Previous 10 | Next 10 |
BioLineRx (BLRX) +62% on positive top-line results from GENESIS phase 3 trial.Cocrystal Pharma (COCP) +40%.Huttig Building Products, Inc. (HBP) +26% on Q1 results.Vaxart (VXRT) +20% as its oral COVID-19 vaccine shows potential to offer promising solution against variants.Precip...
Montrouge, France, May 3, 2021 DBV Technologies Reports Q1 2021 Financial Results DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for th...
Montrouge, France, April 28, 2021 Ordinary and Extraordinary General Meeting of May 19 , 202 1 to be Held in Closed Virtual Session Due to COVID-19 Pandemic DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock ...
Gainers: [[PGNY]] +7.9%. [[XELB]] +7.0%. [[IDYA]] +6.9%. [[LSCC]] +6.6%. [[DKNG]] +6.0%.Losers: [[SPNE]] -3.8%. [[DBVT]] -3.4%. [[SYBX]] -3.0%. [[SESN]] -2.6%. [[DSEY]] -2.5%. For further details see: PGNY, XELB, SPNE and SYBX among after-hours movers
Gainers: Galectin Therapeutics (GALT) +17%, NexImmune (NEXI) +16%, Kymera Therapeutics (KYMR) +15%, Nurix Therapeutics (NRIX) +15%, DBV Technologies (DBVT) +13%.Losers: LifeMD (LFMD) -24%, CorMedix (CRMD) -11%, Cleveland BioLabs (CBLI) -9...
Montrouge, France, April 2, 2021 DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced today the provi...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code:...
Montrouge, France, March 26, 2021 DBV Technologies Announces a New Chair of its Audit Committee and Date of its Annual General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, ann...
Montrouge, France, March 17, 2021 DBV Technologies Announces Filing of 2020 Annual Report on Form 10-K and 2020 Universal Registration Document The Company also announces that it will enter the SBF 120 Index on Euronext DBV Technologies (Euronext: DBV – ISIN: FR00...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN ...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...
Châtillon, France, July 29, 2024 DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, toda...